Androgen Receptor Pathway Inhibitors (ARPIs) Are Superior to Taxanes for Castrate-Resistant Metastatic Prostate Cancer
The first results from the ProBio study show that treatment with ARPI leads to longer PFS, but Henrik Grönberg predicts that there will be many larger publications and results from the study in the future.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
